PR94629

SEOUL, South Korea, Feb. 22, 2022 /PRNewswire=KYODO JBN/ --

- RSVI-301, a new drug candidate adopting miRNA technology, enters the

technology export process.

RosVivo Therapeutics, Inc. (hereinafter referred to as "RosVivo") announced

that it has signed a Material Transfer Agreement (MTA) with one of the largest

global pharmaceutical companies Eli Lilly and Company (hereinafter referred to

as "Eli Lilly") for commercial development of diabetes and obesity treatments.

Material Transfer Agreement indicates a contract to deliver candidate

substances to the other company for verifying the efficacy of the drug

substances through experiments and sharing the research (experimental) results.

MTA is considered as an initial step of processes towards technology export and

license-out.

Conducting considerable experiments with animal models in previous, RosVivo has

collected strong and compelling data for RSVI-301's efficacy compared to GLP-1

receptor agonist. GLP-1 receptor agonist is currently known as a game-changer

to treat diabetes and obesity in the market. Eli Lilly will review and

acknowledge the animal experiment data and ensure the potential of RSVI-301

through this MTA.

RosVivo's RSVI-301 pipeline is the world's first in class new drug candidate

that can fundamentally treat diabetes by restoring the function of beta cells

that secrete insulin, the cause of diabetes, and at the same time lowering

insulin resistance. Currently, diabetes is not fundamentally treated because

diabetes drugs only temporarily lower blood sugar. In addition, RSVI-301 is

considered an ideal next-generation new drug candidate for diabetes treatment

with fewer side effects as it shows excellent therapeutic effects on obesity,

fatty liver and digestive gastrointestinal disorders in animal testing.

An official from the RosVivo said, "The fact that it went through CDA with Eli

Lilly, a global diabetes treatment company, proved the possibility of new drug

candidates and we are also confident in licensing out." He also mentioned as,

"In addition to Eli Lilly, the RosVivo received attention for its candidates

from other global pharmaceutical companies."

SOURCE:RosVivo Therapeutics, Inc.

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=415581